Abstract |
To definitively determine whether the neonatal Fc receptor (FcRn) is required for the acute amelioration of immune thrombocytopenia ( ITP) by IVIg, we used FcRn-deficient mice in a murine ITP model. Mice injected with antiplatelet antibody in the presence or absence of IVIg displayed no difference in platelet-associated IgG between FcRn deficient versus C57BL/6 mice. FcRn-deficient mice treated with high-dose (2 g/kg) IVIg or a low-dose (2 mg/kg) of an IVIg-mimetic CD44 antibody were, however, protected from thrombocytopenia to an equivalent extent as wild-type mice. To verify and substantiate the results found with FcRn-deficient mice, we used β(2)-microglobulin-deficient mice (which do not express functional FcRn) and found that IVIg or CD44 antibody also protected them from thrombocytopenia. These data suggest that for both high-dose IVIg as well as low-dose CD44 antibody treatment in an acute ITP model, FcRn expression is neither necessary nor required.
|
Authors | Andrew R Crow, Sara J Suppa, Xi Chen, Patrick J Mott, Alan H Lazarus |
Journal | Blood
(Blood)
Vol. 118
Issue 24
Pg. 6403-6
(Dec 08 2011)
ISSN: 1528-0020 [Electronic] United States |
PMID | 22001393
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibodies, Monoclonal
- Autoantibodies
- Cd44 protein, mouse
- Histocompatibility Antigens Class I
- Hyaluronan Receptors
- Immunoglobulins, Intravenous
- Receptors, Fc
- beta 2-Microglobulin
- Fc receptor, neonatal
|
Topics |
- Animals
- Antibodies, Monoclonal
(therapeutic use)
- Autoantibodies
(therapeutic use)
- Disease Models, Animal
- Histocompatibility Antigens Class I
(genetics, physiology)
- Humans
- Hyaluronan Receptors
(chemistry)
- Immunoglobulins, Intravenous
(therapeutic use)
- Mice
- Mice, Inbred C57BL
- Mice, Knockout
- Mice, Transgenic
- Platelet Count
- Purpura, Thrombocytopenic, Idiopathic
(blood, immunology, prevention & control)
- Receptors, Fc
(genetics, physiology)
- beta 2-Microglobulin
(genetics, physiology)
|